静脉氨基酸对临时机械循环支持患者的肾脏保护:PROTECTION研究亚组分析
该研究为PROTECTION多中心随机对照试验的二次亚组分析,纳入232例接受临时机械循环支持(tMCS)的心脏手术患者,比较静脉氨基酸(AA)输注与安慰剂对急性肾损伤(AKI)发生率的影响。结果显示AA组AKI发生率显著低于安慰剂组(44.6% vs 60.8%,RR 0.73,95%CI 0.57-0.94,P=0.01),需治疗人数为6,短期AA输注可能减少tMCS患者AKI发生。
要点
- tMCS患者中静脉氨基酸组AKI发生率44.6%,低于安慰剂组60.8%。
- 相对风险0.73(95%CI 0.57-0.94,P=0.01),需治疗人数为6。
- 两组次要结局无显著差异,AA组术前肌酐中位数较高。
核心结论
- 短期静脉氨基酸输注可能降低需要tMCS患者的急性肾损伤发生率。
- 在该肾衰竭高风险人群中,使用氨基酸看来是合理的。
研究设计与样本
- PROTECTION多中心随机对照试验的二次亚组分析,纳入全部接受tMCS的患者。
- 共232例接受tMCS患者,112例随机至氨基酸组,120例至安慰剂组。
- 择期心脏手术体外循环患者随机接受2 g/kg理想体重/天静脉氨基酸(最大100 g/天)或匹配安慰剂,从手术室入室至最长3天、开始肾脏替代治疗、出ICU或死亡。
- 主要结局为急性肾损伤发生率。
主要发现
- 氨基酸组术前血清肌酐中位数显著高于安慰剂组(1.08,四分位距0.90-1.26 vs 0.98,四分位距0.85-1.15;P=0.02)。
- 氨基酸组AKI发生率低于安慰剂组(44.6% vs 60.8%;相对风险0.73;95%置信区间0.57-0.94;P=0.01;需治疗人数=6)。
- 次要结局无显著差异。
关键数值与推荐
- AKI发生率:氨基酸组44.6% vs 安慰剂组60.8%,相对风险0.73(95%CI 0.57-0.94),P=0.01,需治疗人数=6。
- 术前血清肌酐中位数:氨基酸组1.08(IQR 0.90-1.26) vs 安慰剂组0.98(IQR 0.85-1.15),P=0.02。
临床怎么用
- 对于接受tMCS的心脏手术患者,可考虑短期静脉氨基酸输注以降低AKI风险。
- 需结合术前肌酐水平等基线特征评估获益与风险。
局限性
- 为二次亚组分析,样本量有限(232例),结果需进一步验证。
- 氨基酸组术前肌酐显著高于安慰剂组,基线不完全均衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In cardiac surgery patients, acute kidney injury (AKI) frequently occurs in the setting of haemodynamic instability and treatment with temporary mechanical circulatory support (tMCS). Recent evidence suggests amino acids (AA) infusion may reduce AKI rate. However, the effect of AA infusion in patients requiring tMCS may be less effective. METHODS: We performed a secondary analysis of the PROTECTION multicentre randomized controlled trial including all patients treated with tMCS. Patients undergoing elective cardiac surgery with cardiopulmonary bypass were randomized to receive 2 g/kg ideal body weight/day of intravenous AA to a maximum of 100 g/day or matching placebo from operating room admission until up to 3 days, receipt of renal-replacement therapy, discharge from ICU or death. The primary outcome of the PROTECTION study was the rate of AKI, as in this secondary analysis. A total of 3511 patients were randomized in the study. RESULTS: We studied 232 patients who received tMCS, 112 randomized to AA infusion and 120 to placebo. The median preoperative serum creatinine value was significantly higher among AA group patients (AA: 1.08, interquartile range 0.90-1.26; placebo: 0.98, interquartile range 0.85-1.15; P = 0.02). The rate of AKI, however, was lower in patients randomized to AA (44.6% vs 60.8%; relative risk 0.73; 95% confidence interval (0.57-0.94); P = 0.01; number needed to treat = 6). We found no significant differences in secondary outcomes. CONCLUSIONS: Short-term AA infusion appears to reduce rate of AKI among patients requiring tMCS. Use of AA in this population at high-risk for renal failure appears justified. CLINICAL TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT03709264.
引用
- Belletti A, Pisano A, Scandroglio AM, et al. Intravenous amino acids for renal protection in patients receiving temporary mechanical circulatory support: a secondary subgroup analysis of the PROTECTION study. Eur J Cardiothorac Surg. 2025. PMID: 39977357. doi:10.1093/ejcts/ezaf035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。